Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice

Por Ronald Anderson, Ronald Anderson, Bernardo L. Rapoport, Bernardo L. Rapoport
Publicado em 2018-03-01

High Mobility Group Box 1 in Human Cancer

Por Bernardo L. Rapoport, Helen C. Steel, Annette J. Theron, Liezl Heyman, Teresa Smit, Yastira Ramdas, Ronald Anderson
Publicado em 2020-07-01

Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules

Por Bernardo L. Rapoport, Bernardo L. Rapoport, Helen C. Steel, Nomsa Hlatshwayo, Nomsa Hlatshwayo, Annette J. Theron, Pieter W. A. Meyer, Pieter W. A. Meyer, Simon Nayler, Simon Nayler, Carol-Ann Benn, Teresa Smit, Luyanda L. I. Kwofie, Luyanda L. I. Kwofie, Liezl Heyman, Ronald Anderson
Publicado em 2022-05-01